Meaverin (Mepivacaine Hydrochloride)

Meaverin is a local anesthetic used to achieve temporary loss of sensation in specific tissues.

• Dental procedures: provides local anesthesia for extractions, restorations and periodontal surgery.
• Surgical infiltration anesthesia: produces tissue anesthesia for minor skin and soft‑tissue surgeries.
• Epidural anesthesia: offers segmental nerve block for obstetric and lower‑body procedures.
• Intradermal anesthesia: enables precise anesthesia for skin testing and minor dermatologic interventions.

• Mepivacaine Hydrochloride blocks voltage‑gated sodium channels on neuronal membranes, preventing the influx of sodium ions required for depolarisation. This reversible inhibition stops the generation and propagation of nerve impulses, resulting in a temporary loss of sensation in the targeted area.

Adverse reactions may occur following administration of Meaverin.

Common Side Effects

• Transient tingling or numbness at the injection site.
• Mild dizziness or light‑headedness.
• Temporary swelling or bruising around the injection area.
• Mild headache.
• Nausea.
• Temporary visual disturbances.

Serious or Rare Side Effects

• Prolonged or severe nerve block lasting beyond the expected duration.
• Cardiovascular instability such as hypotension or arrhythmia.
• Allergic reactions including rash, urticaria or anaphylaxis.
• Central nervous system toxicity presenting as seizures or altered consciousness.
• Methemoglobinemia.
• Persistent motor weakness.

When using Meaverin, clinicians should observe specific safety measures.

• Patient assessment: evaluate medical history for cardiac, hepatic or renal disease before administration.
• Dosage calculation: ensure dose is calculated by a qualified prescriber based on patient weight and procedure type.
• Monitoring: observe vital signs and neurological status during and after injection.
• Contra‑indications: avoid use in patients with known hypersensitivity to amide‑type local anesthetics.
• Store at ambient temperature: keep in original container, protect from light and moisture, and do not freeze.

Meaverin may interact with other agents that affect cardiac conduction or central nervous system function.

Major Interactions (Avoid)

• Class I anti‑arrhythmic drugs (e.g., quinidine, procainamide): may potentiate cardiotoxicity.
• Beta‑blockers: can exacerbate bradycardia when combined with systemic absorption.

Moderate Interactions (Monitor Closely)

• Other local anesthetics: cumulative toxicity risk.
• CNS depressants (e.g., benzodiazepines, opioids): may increase sedation.
• MAO inhibitors: potential for enhanced hypotensive response.
• Diuretics: may alter plasma protein binding and increase free drug levels.